7 completed, 2 active not recruiting, 1 recruiting. 5 Phase 3, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Active not recruiting 2 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Camurus AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly Octreotide subcutaneous depot - Acromegaly | Recruiting | Camurus AB | 200 | 2026-06-05 | 2026-10-27 | |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET CAM2029, Octreotide LAR, Lanreotide ATG - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | Camurus AB | 332 | 2021-10-22 | 2026-07-28 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot) - Acromegaly | Phase 3 | Completed | Camurus AB | 135 | 2019-10-10 | 2025-12-22 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot), Matching placebo - Acromegaly | Phase 3 | Completed | Camurus AB | 72 | 2019-08-19 | 2026-08-20 |
| Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain buprenorphine, Placebo - Chronic Lower Back Pain, Chronic Pain | Phase 3 | Completed | Braeburn Pharmaceuticals | 1053 | 2016-09-01 | 2021-10-15 |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) octreotide FluidCrystal® injection depot - Acromegaly, Neuroendocrine Tumors | Phase 2 | Completed | Camurus AB | 12 | 2015-01-01 | 2017-12-15 |
| Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer leuprolide acetate FluidCrystal® injection depot, leuprolide acetate - Prostate Cancer | Phase 2 | Completed | Camurus AB | 51 | 2014-09-01 | 2017-04-25 |
| A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis episil(R), Oral hygiene procedures - Oral Mucositis | Not applicable | Completed | Camurus AB | 116 | 2013-02-01 | 2016-03-14 |
| Effects of Mucoprotective Product on Xerostomia XER2020 - Xerostomia | Phase 4 | Completed | Camurus AB | 20 | 2011-02-01 | 2011-11-09 |
Acromegaly (4) · Chronic Pain (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neuroendocrine Tumors (1) · Polycystic Kidney, Autosomal Dominant (1) · Polycystic liver disease (1) · Prostatic Neoplasms (1) · Serotonin Syndrome (1) · Stomatitis (1) · Xerostomia (1)
Buprenorphine (1) · Leuprolide (1) · luprolide acetate gel depot (1)
Germany (7) · United States (5) · Hungary (4) · Italy (4) · Poland (3) · Spain (3) · Sweden (3) · United Kingdom (3) · Belgium (2) · France (2) · Greece (2) · Israel (2) · Netherlands (2) · Russia (2) · Turkey (Türkiye) (2)
Diego Ferone, M.D (1) · Joost Drenth, MD (1) · Karin Garming-Legert, DDS, PhD. (1) · Marianne Pavel, Professor (1) · Pamela Freda, M.D (1) · Simron Singh, MD, MPH (1) · Teuvo Tammela, Prof (1)
PMID 40418492, PMID 30535537, PMID 38229199, PMID 39356039, PMID 39378125
2019 (2), 2023 (1)